Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

Nature Medicine 2026 Open access

Read full text
Authors: Princess U. Ogbogu, Florence E. Roufosse, Praveen Akuthota, Piotr Kuna, Matthieu Groh, Andreas Reiter, Akira Yokota, Salman H. Siddiqui, Pim G. N. J. Mutsaers, Bing Li, Paneez Khoury, Lila M. Bahadori
+11 more Artur Bednarczyk, Gerben Bouma, Laura Brooks, Jorge Ferreira, Hanna Grindebacke, Calvin N. Ho, Priya Jain, Rebecca L. Palmer, Maria L. Jison, Amy D. Klion, on behalf of NATRON study group
DOI: 10.1038/s41591-026-04425-3
Cited by: 1

Abstract

In the version of this article initially published, there was an error in Table 1 where the PROMIS Fatigue median for the total population, now reading “55.1” appeared originally as “51.1.” In addition, errors in Supplementary Table 2 values have now been updated as follows: Eosinophil count median + Benralizumab (n = 67 ) has been changed from 1,070.0 (230–5,620) to 1,085.0 (360–5,620); Eosinophil count median + Total ( N = 133) has been changed from 1,120.0 (60–20,910) to 1,100.0 (60–20,910); and Prior HES-related biologic therapy in the past 12 months for Omalizumab + Benralizumab ( n = 67) has been changed from 2 (1.5%) to 2 (3.0%). The tables have been updated in the HTML and PDF versions of the article.

Fields of Study & Subjects

Eosinophilic Disorders and Syndromes Eosinophilic Esophagitis IgG4-Related and Inflammatory Diseases

Publication details

Journal / source
Nature Medicine
Publisher
Springer Science and Business Media LLC
Volume
32
Issue
6
Pages
2319–2319
Publication date
5 May 2026
Language
EN